Related references
Note: Only part of the references are listed.Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD)
Adam Bucki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Revised Pharmacophore Model for 5-HT2A Receptor Antagonists Derived from the Atypical Antipsychotic Agent Risperidone
Urjita H. Shah et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Platelet Serotonin Aggravates Myocardial Ischemia/Reperfusion Injury via Neutrophil Degranulation
Maximilian Mauler et al.
CIRCULATION (2019)
Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT2A and α2-adrenoceptor antagonistic properties. A comparison with ketanserin, sarpogrelate, prazosin, yohimbine and ARC239
Monika Kubacka et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis
Fanrui Mo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes
Dong-Hwa Lee et al.
ATHEROSCLEROSIS (2017)
Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent
Anna Czopek et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Use of Novel Antiplatelet Agents in Acute Coronary Syndromes
Michael Luna et al.
CURRENT ATHEROSCLEROSIS REPORTS (2015)
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Stephen D. Wiviott et al.
LANCET (2015)
Antiplatelet drug resistance: Molecular insights and clinical implications
Christopher N. Floyd et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
Structural Features for Functional Selectivity at Serotonin Receptors
Daniel Wacker et al.
SCIENCE (2013)
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations
Piera Capranzano et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2013)
Serotonin Antagonism Improves Platelet Inhibition in Clopidogrel Low-Responders after Coronary Stent Placement: An In Vitro Pilot Study
Daniel Duerschmied et al.
PLOS ONE (2012)
Platelet receptor signaling in thrombus formation
David Stegner et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity
Anna Czopek et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
APD791, 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology
John W. Adams et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Evaluating virtual screening methods: Good and bad metrics for the early recognition problem
Jean-Francois Truchon et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Functions of 5-HT2A receptor and its antagonists in the cardiovascular system
T Nagatomo et al.
PHARMACOLOGY & THERAPEUTICS (2004)
Share Paper
